July 8, the Food and Drug Administration (FDA) submitted a report to Congress on the state about the CBD marketplace. The document shows studies about the contents and quality of cannabis-derived products that the agency has tested over the past six years.
The report is a response to a mandate that attached to congressional appropriations legislation last year. Because this report shows vital inconsistencies between cannabinoid concentrations listed on labels and the specific components in products, besides, it found negligible evidence to prove some dangerous metals and minerals are added to products.
Reform advocates emphasized that quality control in the market needs to be ensured, so the FDA has to develop regulations. The agency is now creating those rules. However, CBD and related products are still allowed to be sold while prioritizing enforcement action against companies that make claims about the medical benefits of their products.
The agency wrote:
“FDA recognizes the significant public interest in CBD products… However, there are many questions about the characteristics of currently marketed CBD products because the Agency lacks significant information on what CBD-containing products are on the market, and there are little data available on those products themselves.”
And according to a report, it pointed out:
“FDA believes that understanding the characteristics of marketed CBD products is critical to making informed decisions about how best to protect public health in the current marketplace.”
Also, the report continuously said,
“Together, this information will provide the Agency with a better understanding of product characteristics in the current CBD marketplace and will help protect and promote public health.”
This article is issued by Marijuana Moment, for more information, please check: